Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
dulanermin · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | - |
| Cohorts 1-5 | EXPERIMENTAL | - |
| Cohorts 6, 6A, 7, 7A | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| FOLFOX regimen | DRUG | Intravenous repeating dose |
| bevacizumab | DRUG | Intravenous repeating dose |
| dulanermin | DRUG | Intravenous repeating dose |
| FOLFIRI regimen | DRUG | Intravenous repeating dose |
| cetuximab | DRUG | Intravenous repeating dose |
| irinotecan | DRUG | Intravenous repeating dose |
Inclusion Criteria: * Histologically confirmed CRC with evidence of locally advanced recurrent or metastatic disease (i.e., by radiographic imaging or biopsy) and measurable tumor lesions * Life expectancy \> 3 months * For patients of reproductive potential (males and females), use of reliable mea...
Top 20 of 77 competitors
Dulanermin is an investigational small molecule being studied for the treatment of colorectal cancer, including metastatic colorectal cancer. It is being developed by Roche Holding AG (ticker: RHHBY) and is currently in Phase 1 clinical development.
The molecular target of dulanermin has not been disclosed in available information. As a small molecule in oncology, it is being investigated for its potential role in treating colorectal cancer, but its specific mechanism of action is not publicly detailed.
Dulanermin is being developed by Roche Holding AG, a multinational healthcare company traded under the ticker RHHBY. The drug is currently in Phase 1 clinical trials for colorectal cancer indications.
Dulanermin is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 1 trials have been completed, both studying the drug in combination with other therapies for colorectal cancer.
Dulanermin has been studied in two completed Phase 1 trials. NCT00671372 evaluated dulanermin with Camptosar/Erbitux chemotherapy or FOLFIRI (with or without bevacizumab) in previously treated metastatic colorectal cancer. NCT00873756 tested dulanermin with FOLFOX and bevacizumab in previously untreated colorectal cancer.
No alternative names for dulanermin have been reported. The drug is known only by its single name, dulanermin, in clinical trial records and development documentation.